Clinical Trials Logo
  1. Home
  2. Essential Hypertension
  3. NCT00220233
  4. Details
NCT00220233 Clinical Trial

Olmesartan as an add-on to Amlodipine in Hypertension

Essential Hypertension Clinical Trial

Official title:
Add-on Study of Olmesartan Medoxomil in Patients With Moderate to Severe Hypertension Not Achieving Target Blood Pressure on Amlodipine 5 mg Alone

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00220233
Other study ID # CS8663-A-E303
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date April 2005
Est. completion date August 2007

Study information
Verified date December 2007
Source Daiichi Sankyo, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is to test the efficacy and safety of the combination of olmesartan and amlodipine in hypertensive patients whose blood pressure is not adequately controlled with amlodipine alone

Recruitment information / eligibility
Status Completed
Enrollment 632
Est. completion date August 2007
Est. primary completion date
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Without antihypertensive pre-treatment mean seated BP greater than 160/100 mmHg

- Pre-treatment with amlodipine 5 or 10 mg: mean seated BP greater than or equal to 140/90 mmHg

Exclusion Criteria:

- Secondary hypertension

- Any serious disorder which may limit the ability to evaluate the efficacy or safety of the test drugs

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• olmesartan medoxomil

• amlodipine

• hydrochlorothiazide

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Sankyo Pharma Gmbh

Country where clinical trial is conducted

Germany, 

Outcome
Type Measure Description Time frame Safety issue
Primary Mean change in trough seated diastolic blood pressure
Secondary Mean change in trough seated systolic BP
Secondary Mean change in daytime, nighttime and 24 hour ambulatory blood pressure
Secondary Percent of patients achieving target blood pressure goal
Secondary Safety and tolerability
See also
  Status Clinical Trial Phase
Recruiting NCT03708601 - Prognostic Risk of Patients With Essential Hypertension for Cardiovascular Events (PROSPECT)
Not yet recruiting NCT05503953 - Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS Phase 3
Recruiting NCT05526703 - Clinical Trial to Evaluate the Efficacy and Safety of D064 and D701 Combination Therapy Phase 3
Completed NCT06395194 - Effects of Valsartan vs Amlodipine and Low BP on Kidney Outcomes in Essential Hypertension Phase 3
Not yet recruiting NCT06418074 - Effects of Exogenous Ketosis on Renal Function, Renal Perfusion, and Sodium Excretory Capacity N/A
Completed NCT02890173 - Study of CS-3150 in Patients With Essential Hypertension Phase 3
Withdrawn NCT02096939 - Microvascular Function in Primary Aldosteronism N/A
Completed NCT02944734 - Comparison of Efficacy and Safety of Combination Therapy and Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension Phase 2
Recruiting NCT01956786 - Efficacy of Amlodipine-Folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine Phase 2/Phase 3
Completed NCT02553512 - Helius in Hypertension-I: The UK Hypertension Registry N/A
Completed NCT01198249 - Pharmacokinetic Drug Interactions Between Single and Concomitant Administrations of Amlodipine, Losartan, and Hydrochlorothiazide in Subjects With (Pre)Hypertension Phase 1
Completed NCT01001572 - Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension Phase 3
Recruiting NCT00380289 - Early Metabolic Changes With Thiazide or Beta Blocker Therapy for Essential Hypertension N/A
Completed NCT00139698 - Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension Phase 3
Completed NCT00288184 - Uric Acid in Essential Hypertension in Children Phase 2
Completed NCT01289886 - Fimasartan (BR-A-657) Single Oral Dose in Healthy Subjects Phase 1
Not yet recruiting NCT06041529 - Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension Phase 4
Completed NCT04470830 - A Study for PMS of AZL-M/CLD FDC in the Treatment of Participants With Essential HTN in South Korea
Completed NCT00758524 - A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension Phase 2
Recruiting NCT05109013 - Juvenile Essential Arterial Hypertension and Vascular Function